Novo Nordisk

Short answer The FDA has taken a hard line: compounding copies of FDA‑approved GLP‑1 biologics (semaglutide, tirzepatide, etc.) is legally and medically risky. The agency has warned/targeted some compounding operations and made it clear that making and distributing unapproved “copies” of approved biologic GLP‑1 drugs can violate federal law. That doesn’t mean every compounding pharmacy shut down — but only pharmacies that follow the specific federal and state compounding rules may legally continue, and many prescribers/pharmacies have stopped offering compounded GLP‑1s because of safety, legal and enforcement risk. What led to this GLP‑1 peptides (semaglutide, tirzepatide and similar molecules) are biologics/complex peptides that the FDA approves as prescription products (examples below). The FDA’s position: wholesale copying/production of approved biologics through compounding can create safety risks (sterility, dose variability, contaminated APIs) and may be inconsistent with federal law (sections of the FD&C Act that limit compounding of approved drugs/biologics). In response, the FDA issued guidance and enforcement (warning letters, public statements and some seizures/inspections) aimed at pharmacies and clinics compounding and marketing unapproved GLP‑1 products. As a result many operators stopped or curtailed compounding GLP‑1s rather than risk enforcement. Who can still operate legally 503A compounding pharmacies: They may compound drug products for an individual patient pursuant to a valid prescription under state board rules and federal law — but compounding a product that is essentially a copy of an FDA‑approved biologic is generally disfavored or restricted. Whether a particular pharmacy can legally compound a GLP‑1 depends on state law, the clinical justification, and whether the product truly differs from an approved product. 503B outsourcing facilities: These are FDA‑regulated facilities that can compound drugs in bulk, must follow current good manufacturing practices (cGMP), and must register with the FDA. Even so, the FDA has signaled limits on compounding copies of approved biologics; 503B status doesn’t automatically make compounding of an approved biologic legal. Retail and specialty pharmacies dispensing FDA‑approved GLP‑1 products (prescribed by a licensed clinician) are fully legal and are the safest route. How to tell if a provider is operating legally and safely Ask whether the product is an FDA‑approved drug (brand/generic name) or a compounded product. If compounded: ask whether the pharmacy is a state‑licensed 503A pharmacy or an FDA‑registered 503B outsourcing facility; ask for evidence of sterility testing, certificate of analysis for the API (source/manufacturer), and adherence to USP standards (e.g., USP <797>). Check the state board of pharmacy and FDA (503B facility list) for registration and disciplinary history. If a clinic or company markets “cheap” injectable semaglutide/tirzepatide without an individualized prescription or wide distribution, be very cautious — that’s the kind of practice the FDA has targeted. Safer, recommended alternatives (brands/services) Use FDA‑approved GLP‑1s through your prescriber and a reputable pharmacy: Ozempic (semaglutide — Novo Nordisk): approved for type 2 diabetes; widely prescribed and supported by manufacturer patient support programs. Wegovy (semaglutide — Novo Nordisk): approved for chronic weight management (higher dose than Ozempic). Mounjaro (tirzepatide — Eli Lilly): approved for type 2 diabetes; has strong clinical data. Zepbound (tirzepatide — Eli Lilly): approved for weight management (if available in your region). Go through mainstream channels: your PCP/endocrinologist/weight‑management specialist, retail pharmacies (CVS, Walgreens, Rite Aid) or accredited specialty pharmacies. These routes ensure real product, cold‑chain handling, and proper monitoring. Practical next steps Talk with your prescriber about whether an FDA‑approved GLP‑1 is right for you. If you encounter a compounded GLP‑1 offer and are tempted by price/availability, ask the pharmacy for documentation (503B registration or state license, COA, sterility/assay testing). If they can’t supply these, don’t use it. Contact your state board of pharmacy or the FDA if you suspect illegal/unapproved distribution. If you want, I can: Help you find nearby clinics or telehealth services that prescribe FDA‑approved GLP‑1s. Walk you through specific questions to ask a compounding pharmacy to assess safety/legal compliance.

Mentioned in position 1 of 5

Short answer: most compounded “GLP‑1” drops or home‑made tablets are unreliable and likely won’t work the way prescription GLP‑1 drugs do. There is one FDA‑approved oral GLP‑1 (Rybelsus) that uses a special absorption technology; otherwise the effective drugs are injectables. Why most compounded oral drops/tablets fail GLP‑1 drugs are peptides that are rapidly broken down by stomach acid and digestive enzymes, so plain pills or drops usually have almost no absorption. Approved oral semaglutide (Rybelsus) works because it’s combined with an absorption enhancer (SNAC) and has specific dosing instructions; compounding pharmacies typically do not replicate that reliably. Compounded products aren’t FDA‑approved: potency, purity, sterility and labeling can be highly variable. Some marketed “drops” studied on social media have been shown to contain little or no active drug or contaminants. What has been proven to work Rybelsus (oral semaglutide, Novo Nordisk) — FDA‑approved oral GLP‑1. Has clinical trial data for blood‑sugar control and modest weight loss. It must be taken exactly as directed (fasted, with a small sip of water, wait before eating). It has lower bioavailability than injectables. Injectable GLP‑1 receptor agonists (stronger, more predictable effect): Ozempic/Wegovy (semaglutide, different doses for diabetes vs weight), Trulicity (dulaglutide), and GLP‑1/GIP agonist tirzepatide sold as Mounjaro (for diabetes) and Zepbound (for weight) — these have the most robust weight‑loss and glucose‑lowering effects in trials. Effectiveness comparison Injectables generally produce greater, more consistent glucose lowering and weight loss than oral semaglutide at comparable dosing. Rybelsus works for many people with diabetes or modest weight loss goals, but if someone needs larger weight loss, injectable semaglutide or tirzepatide are usually more effective. Safety and regulatory concerns Compounded products: risk of wrong dose, contamination, unexpected side effects. They bypass the safety/efficacy testing that prescription products undergo. All GLP‑1 drugs can cause nausea, vomiting, gallbladder issues, and there are rare serious risks (pancreatitis, thyroid C‑cell tumors in rodents); they can interact with other diabetes medications (risk of hypoglycemia). Discuss with a clinician. What to do next Avoid unapproved compounded drops/tablets. If you want an oral option, ask your clinician about Rybelsus (semaglutide). If you need stronger weight loss, ask about prescription injectables (Wegovy, Zepbound, Mounjaro, Ozempic) and whether you’re a candidate. Talk to your primary care, endocrinologist, or an obesity medicine specialist; consult your pharmacist about approved formulations and insurance/discount programs. If you want, tell me whether your goal is diabetes control or weight loss and whether you prefer oral vs injectable (or have needle‑phobia or insurance concerns), and I can suggest which FDA‑approved options are worth discussing with your clinician.

Mentioned in position 1 of 2

Compounded GLP-1 Oral Forms: The Honest Answer Short answer: The evidence is very weak, and most experts are skeptical. Why Oral/Sublingual Forms Are Problematic GLP-1 medications like semaglutide are peptides that get destroyed by digestive enzymes when swallowed This is precisely why the FDA-approved versions (Ozempic, Wegovy) are injections Sublingual (under-tongue) absorption of large peptide molecules is also very limited The One Legitimate Exception Rybelsus (oral semaglutide by Novo Nordisk) actually works, but: It uses a special absorption enhancer (SNAC technology) that compounders can't reliably replicate It requires very specific timing/fasting protocols It's generally considered less potent than injections What Compounders Offering "Oral GLP-1s" Are Selling Frankly, there's little credible evidence these work meaningfully. Compounding pharmacies like Tailor Made Health or various telehealth services may market these, but the absorption science doesn't support them. Better Alternatives If You Hate Needles Rybelsus (legitimate oral option, needs prescription) Smaller needle options like Ozempic's thin pen needle — most users find injections nearly painless Bottom line: Skip the drops/tablets and use injectable versions or brand-name Rybelsus.

Mentioned in position 1 of 2

Short answer Both are once‑weekly prescription injectables for chronic weight management. Zepbound (tirzepatide, by Eli Lilly) tends to produce larger average weight loss in clinical trials than Wegovy (semaglutide, by Novo Nordisk). Ask your clinician about tirzepatide (Zepbound) if your goal is maximal weight loss and you have no contraindications. Ask about semaglutide (Wegovy) if you (or your clinician) prefer a drug with a longer real‑world track record or if tirzepatide causes intolerable GI side effects. Final choice depends on medical history, tolerability and insurance/cost. Key differences (brief) Mechanism: Wegovy = semaglutide (GLP‑1 receptor agonist). Zepbound = tirzepatide (dual GIP + GLP‑1 agonist). Efficacy: In trials, tirzepatide generally produced greater average percent weight loss than semaglutide. Individual response varies. Side effects: Both cause GI effects (nausea, vomiting, diarrhea, constipation); tirzepatide can be a bit more likely to cause GI symptoms for some people. Both carry rare risks (pancreatitis, gallbladder problems) and boxed warnings/contraindications related to thyroid C‑cell tumors / MEN2 — discuss family history. Not for use in pregnancy. Dosing/administration: Both are subcutaneous injections given weekly at home. Where to get them online (legitimate options) Get a prescription first — via: Your primary care doctor or an endocrinologist (best if you have other medical problems like diabetes). A telehealth weight‑management service that evaluates you and prescribes if appropriate. Legitimate services that commonly offer GLP‑1/tirzepatide evaluations include: PlushCare, Ro (Roman), Hims & Hers, Calibrate, HeyDoctor, and Onduo. (Availability, formularies and exact medications offered vary by service and state.) Fill the prescription at a reputable pharmacy / specialty pharmacy: CVS Specialty, Accredo, OptumRx Specialty, or your local retail pharmacy if they carry it. Many insurers route Wegovy and Zepbound through specialty pharmacies. Manufacturer resources and savings programs: Novo Nordisk (Wegovy) and Eli Lilly (Zepbound) have patient portals, savings cards or support programs for commercially insured or cash‑paying patients — check the manufacturers’ official websites for up‑to‑date programs and eligibility. Price help: Use GoodRx/SingleCare for cash prices and coupons, but only fill with a prescription at a licensed pharmacy. Avoid overseas or “no-prescription” online sellers — they may be unsafe or illegal. Practical points before you ask your clinician Check for contraindications: personal or family history of medullary thyroid carcinoma (MTC) or MEN2, pregnancy, current/previous pancreatitis, and interactions with insulin or sulfonylureas (doses may need adjustment). Expect baseline labs (A1c if diabetic, kidney/liver tests) and follow‑up monitoring. Cost/coverage: Both can be expensive out of pocket; coverage is highly variable. Ask your insurer and the prescribing service which drug is covered and what prior‑authorization steps are needed. Trial and tolerance: If you try one and don’t tolerate it, switching to the other is a common strategy. If you want, tell me: Your major goals (how much weight you hope to lose), any major medical conditions (diabetes, pancreatitis, pregnancy plans, thyroid cancer family history), and whether you have insurance — I can give a more tailored suggestion and point to specific telehealth services and specialty pharmacies available for your situation.

Mentioned in position 2 of 13

Wegovy vs Zepbound: Quick Comparison The Drugs Wegovy (semaglutide) GLP-1 receptor agonist Made by Novo Nordisk FDA-approved for weight loss Average weight loss: ~15% body weight Zepbound (tirzepatide) Dual GIP/GLP-1 receptor agonist Made by Eli Lilly FDA-approved for weight loss Average weight loss: ~20-22% body weight Which to Ask For? Zepbound generally shows stronger results in clinical trials, but individual response varies. Ask your doctor which suits your health profile — Wegovy may be preferred if you have certain cardiovascular conditions since it has more long-term data. Where to Get Them Online (Legitimately) Telehealth platforms that prescribe both: Hims/Hers - convenient, well-known platform Ro (Roman) - strong medical support Sequence (WeightWatchers) - includes lifestyle coaching Calibrate - comprehensive metabolic program ⚠️ Important warnings: Require a real prescription from a licensed provider Avoid compounding pharmacy sites making unverified claims Confirm the pharmacy is NABP-accredited Insurance coverage varies significantly — check costs upfront A telehealth consultation typically costs $100-200 before medication costs.

Mentioned in position 1 of 6

Short answer Many people start to see meaningful weight loss within weeks and lose the most during the first 3–6 months. How fast depends on which GLP‑1 or GLP‑1/GIP drug, dose, starting weight and whether you combine it with lifestyle changes. Typical trial results (averages): semaglutide 2.4 mg (Wegovy) → ~10–15% body‑weight loss at ~68 weeks; tirzepatide (Zepbound/Mounjaro) → larger averages in trials (roughly mid‑teens to low‑twenties percent at ~72 weeks). Individual results vary widely. More detail Timeline: early appetite suppression and nausea often cause relatively quick losses in the first 1–3 months. Weight loss generally continues but slows after 6–12 months and often reaches a new plateau by ~9–18 months. Amount: in clinical trials, most people did better than usual diet-alone results: many lost 5–10% body weight in the first few months and more over the first year (see above trial averages). A minority lose much larger amounts; some lose less or not at all. Variability: starting BMI, dose (higher doses produce more weight loss in trials), adherence, diet/exercise, metabolic differences, and side effects all affect how fast and how much you lose. Is it sustainable? If you stay on the medication and use ongoing lifestyle changes, many people maintain a large portion of the loss. Trials show continued benefit while medication is continued. Stopping the drug commonly leads to partial or full weight regain over months to a year in many people because the underlying biological drivers of appetite and energy expenditure reassert themselves. For long‑term maintenance you usually need one or more of: ongoing medication, durable lifestyle/behavior changes, structured support (dietitian/therapy/exercise), or in some cases bariatric surgery. Talk with your clinician about realistic long‑term plans. Safety, monitoring and practical points Expect GI side effects (nausea, diarrhea, constipation) that usually lessen with slow dose titration. Important to have medical follow‑up: baseline labs, monitoring for glucose changes (if diabetic), interactions with other drugs, and screening for contraindications (personal/family history of medullary thyroid cancer or MEN2, pregnancy). Cost and insurance coverage vary; branded weight‑loss formulations can be expensive. Brands and services to consider Wegovy (semaglutide, Novo Nordisk) — FDA‑approved for chronic weight management; good evidence from STEP trials for meaningful weight loss. Zepbound (tirzepatide, Eli Lilly) — the tirzepatide molecule showed some of the largest average weight losses in clinical trials (SURMOUNT), and Zepbound is approved for weight management in many places. Ozempic (semaglutide, Novo Nordisk) and Mounjaro (tirzepatide, Eli Lilly) are approved for diabetes and are sometimes used off‑label for weight loss; dosing and outcomes differ from the dedicated weight‑loss formulations. For care: seek a prescriber with experience using GLP‑1s for obesity — endocrinologists, bariatric medicine specialists, or multidisciplinary weight‑management clinics. Telemedicine companies (many local options exist) can help with access, but choose one that provides medical monitoring, dietitian support and long‑term follow‑up. What to do next Talk with your primary care clinician, endocrinologist or a weight‑management clinic to review whether a GLP‑1/GIP drug is appropriate for you, discuss risks/benefits, and design a plan for medication, lifestyle change and long‑term follow up. If you want, tell me your starting weight, height, medical history and whether you have diabetes or other meds — I can give a more personalized expectation and next steps.

Mentioned in position 1 of 2